📊 Key Data
  • Cancer cell viability reduction: 3% in two models and 26% in a third after 96 hours with combination therapy.
  • Proteasome activity drop: 25% of untreated control after 24 hours with combination therapy vs. 52% with carfilzomib alone.
  • Synergistic effect observed: In 28 of 33 solid-tumor models across 14 different tumor types.
🎯 Expert Consensus

Experts would likely conclude that NuCana's NUC-7738 demonstrates significant potential as a combination therapy, particularly in overcoming proteasome inhibitor resistance in multiple myeloma and other cancers, though further clinical validation is required.

about 8 hours ago

The Mechanics of Synergy: NuCana Unlocks Proteasome Sensitization in Myeloma

BARCELONA, Spain – November 20, 2026 – In the global biopharmaceutical sector, strategic leverage is rarely found in a single, isolated breakthrough. More often, it is discovered in the mechanics of synergy—when one molecule unlocks the hidden vulnerabilities of a disease, amplifying the power of existing therapies. NuCana plc has just demonstrated this kind of molecular leverage at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, presenting preclinical data that could fundamentally alter the strategic rationale for its lead pipeline candidate, NUC-7738.

The clinical-stage biopharmaceutical company revealed that NUC-7738, an investigational compound built on its proprietary ProTide technology, dramatically enhances the anti-cancer activity of carfilzomib, an approved and widely prescribed proteasome inhibitor. In multiple myeloma cell models, the combination of the two agents reduced cancer cell viability to a staggering 3% in two models and 26% in a third after 96 hours.

For a company whose primary clinical focus has been on solid tumors, specifically melanoma, this data represents more than just a scientific curiosity. It exposes a novel mechanism of action that could reposition NUC-7738 as a critical combination agent in hematological malignancies, forcing a recalculation of the competitive landscape in multiple myeloma care.

Beyond RNA: Uncovering a Novel Mechanism of Action

To understand the magnitude of NuCana’s findings, one must look at the underlying mechanics of its ProTide technology. The platform is designed to transform conventional nucleoside analogs into more effective medicines by generating significantly higher concentrations of active anti-cancer metabolites directly within cancer cells. Until now, the strategic narrative surrounding NUC-7738 centered on its ability to disrupt RNA polyadenylation, thereby profoundly impacting gene expression and targeting multiple aspects of the tumor microenvironment.

However, the data presented in Barcelona uncovers an entirely new dimension of the drug's utility. Researchers discovered that NUC-7738’s active metabolite alters proteasome function by modulating the opening of the proteasome’s gate, effectively rolling out the red carpet for carfilzomib to enter and execute its cell-killing function.

Crucially, the compound also appears to suppress the processed form of NFE2L1 (also known as NRF1). In the realm of oncology, NFE2L1 is notorious. It is a critical transcription factor that triggers the "proteasome bounce-back effect." When a cancer cell’s proteasome system is inhibited by a drug like carfilzomib, NFE2L1 activates to induce the expression of new proteasome-related genes, allowing the cancer to survive and develop resistance. By downregulating processed NFE2L1, NUC-7738 effectively disarms the cancer cell’s primary defense mechanism against proteasome inhibitors.

In one model presented at the symposium, proteasome activity dropped to just 25% of the untreated control after 24 hours with the combination therapy, compared to 52% with carfilzomib alone. This is the molecular equivalent of cutting off a besieged city's supply lines while simultaneously breaching its gates.

The Multiple Myeloma Battlefield and Carfilzomib Resistance

The strategic implications of this mechanism are vast, particularly in multiple myeloma. The disease is heavily dependent on the proteasome system to manage the massive protein load generated by malignant plasma cells. Carfilzomib, marketed as Kyprolis, is a cornerstone of treatment, particularly in relapsed or refractory settings.

Yet, despite the efficacy of proteasome inhibitors, drug resistance remains an inevitable and fatal hurdle. Patients often cycle through therapies as their cancer cells adapt, upregulate proteasome subunits, and activate alternative survival pathways. While the multiple myeloma landscape has recently been energized by advanced immunotherapies, CAR T-cell treatments, and bispecific antibodies, these options are often reserved for heavily pretreated patients and come with complex logistical and safety profiles.

A small-molecule combination therapy that can resensitize resistant myeloma cells to a known entity like carfilzomib offers immense clinical and commercial leverage. It provides a highly accessible, easily administered regimen that could be slotted into earlier lines of therapy. Industry analysts note that overcoming the NFE2L1-mediated bounce-back effect has long been a holy grail in myeloma research, and NuCana’s ProTide technology may have inadvertently stumbled upon a viable key to that lock.

A Calculated Pipeline Expansion

The synergy extends far beyond multiple myeloma. In a separate, expansive laboratory screen evaluating NUC-7738 alongside 70 partner drugs across 35 distinct cancer cell lines, carfilzomib ranked first in greater-than-expected combination activity. This synergistic effect was observed in 28 of 33 solid-tumor models spanning 14 different tumor types.

“These findings add an important dimension to our understanding of NUC-7738’s mode of action,” stated Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. “What is particularly encouraging is that the changes in proteasome function were accompanied by greater-than-expected anti-cancer activity in these preclinical models. We believe these data strengthen the rationale for further evaluation of NUC-7738 in combination with proteasome inhibitors and across additional tumor types.”

For NuCana, this broad-spectrum synergy presents a lucrative but complex strategic pivot. The company now possesses preclinical justification to expand its pipeline into a wide array of solid and hematological indications. However, in the current biopharmaceutical ecosystem, expanding a clinical footprint requires immense capital, rigorous trial design, and a delicate balance of resource allocation.

Balancing Ambition with Capital Realities

The boardroom calculus for NuCana over the next 24 months will be defined by how it balances these new, expansive opportunities against its near-term clinical milestones. The company has explicitly stated that its immediate priority remains defining the optimal clinical development path for NUC-7738 in melanoma.

All eyes are currently on the upcoming ESMO Immuno-Oncology & Advanced Therapies Congress in London, scheduled for December 14–16, 2026. There, NuCana plans to present final results from the Phase 2 expansion cohort of the NuTide:701 study, which evaluates NUC-7738 in combination with the PD-1 inhibitor pembrolizumab in patients with PD-1 inhibitor-resistant metastatic melanoma. Success in this trial is critical; it will dictate the tone of the company’s ongoing dialogue with the FDA regarding a potential registrational strategy.

Yet, the EORTC-NCI-AACR data provides a powerful hedge. By establishing a scientifically rigorous rationale for expanding beyond PD-1 inhibitor-resistant melanoma, NuCana is diversifying its strategic portfolio. The company noted that its current cash resources are anticipated to fund planned operations into 2029. This financial runway is a vital asset, providing the breathing room necessary to advance its melanoma priorities while simultaneously selecting the most promising combination strategies for further development.

In the intricate flows of capital and innovation that govern the biotech sector, NuCana has effectively increased its optionality. Whether NUC-7738 ultimately makes its mark by breaking through immunotherapy resistance in melanoma, or by dismantling the proteasome defenses of multiple myeloma, the underlying mechanics of its synergy have proven to be a formidable new variable in the fight against cancer.

Topics & Related

Event:
Clinical & Scientific
Theme:
Drug Development
Sector:
Biotechnology
Oncology
Product:
Oncology Drugs

📝 This article is still being updated

Are you a relevant expert who could contribute your opinion or insights to this article? We'd love to hear from you. We will give you full credit for your contribution.

Contribute Your Expertise →
UAID: 55663